Vasculonics was awarded a $2.2 million Phase II SBIR grant to develop a first-in-class disease modifying therapy for pulmonary arterial hypertension.
class="entry-header"
Vasculonics was awarded a $2.2 million Phase II SBIR grant to develop a first-in-class disease modifying therapy for pulmonary arterial hypertension.